A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of Venous Leg Ulcers (VALUE)
Latest Information Update: 30 Apr 2025
At a glance
- Drugs EscharEx (Primary)
- Indications Leg ulcer; Varicose ulcer; Wounds
- Focus Adverse reactions; Registrational
- Acronyms VALUE
- Sponsors MediWound
Most Recent Events
- 28 Apr 2025 According to a MediWound media release, the company announced it will provide an update on the VALUE Phase III study design and enrollment progress at the Symposium on Advanced Wound Care (SAWC) Spring 2025, taking place April 30-May 3 in Grapevine, Texas.
- 24 Apr 2025 Planned End Date changed from 1 Oct 2026 to 1 Mar 2027.
- 24 Apr 2025 Planned primary completion date changed from 1 Oct 2026 to 1 Dec 2026.